OOIR: Observatory of International Research

Papers

(The TQCC of Alimentary Pharmacology & Therapeutics is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease	117
Systematic review: the global incidence of faecal microbiota transplantation‐related adverse events from 2000 to 2020	109
Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world	109
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging	109
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment	81
Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma	81
Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis	58
Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH	57
Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations	55
Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases	55
Systematic review with meta‐analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma	53
Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents	52
Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders	51
Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study	50
Systematic review with meta‐analysis: Time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease	50
Longitudinal association of magnetic resonance elastography‐associated liver stiffness with complications and mortality	49
Umbrella review of 42 systematic reviews with meta‐analyses: the safety of proton pump inhibitors	49
Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Austral	48
Systematic review with meta‐analysis: COVID‐19 outcomes in patients receiving anti‐TNF treatments	47
Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study	47
Review article: emerging drug therapies in inflammatory bowel disease	46
Direct healthcare costs of Rome IV or Rome III‐defined irritable bowel syndrome in the United Kingdom	45
Alcohol‐associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics	45
Incidence, outcomes, and impact of COVID‐19 on inflammatory bowel disease: propensity matched research network analysis	44
Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure	44

Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult‐to‐treat primary biliary cholangitis	44
Impact of Rome IV irritable bowel syndrome on work and activities of daily living	44
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study	41
Novel impedance‐pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro‐oesophageal reflux disease according to Lyon Consensus	41
Systematic review with meta‐analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations	41
Systematic review with meta‐analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B	41
Meta‐analysis: prevalence of, and risk factors for, non‐alcoholic fatty liver disease in patients with inflammatory bowel disease	39
Meta‐analysis: global prevalence, trend and forecasting of non‐alcoholic fatty liver disease in children and adolescents, 2000–2021	39
Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn’s disease	39
Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis	39
Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study	36
Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study	36
Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn’s disease	36
Review article: obesity and colorectal cancer	36
Systematic review and meta‐analysis: the incidence and prevalence of paediatric coeliac disease across Europe	35
Systematic review with meta‐analysis: dietary intake in adults with inflammatory bowel disease	35
Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders	35
Comparison of short‐ and long‐term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor therapy	34
Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin	34
2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus‐related infection before and after liver transplant	34
Review article: the future of microbiome‐based therapeutics	33
Systematic review with meta‐analysis: The effects of non‐steroidal anti‐inflammatory drugs and anti‐platelet therapy on the incidence and recurrence of hepatocellular carcinoma	33
Randomised clinical trial: comparison of tegoprazan and placebo in non‐erosive reflux disease	32
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study	32
Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease	32
Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone	32
Review article: time to revisit Child‐Pugh score as the basis for predicting drug clearance in hepatic impairment	32
Risk of severe COVID‐19 in patients treated with IBD medications: a French nationwide study	31
Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database	31
A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014	31
Systematic review with meta‐analysis: artificial intelligence in the diagnosis of oesophageal diseases	31
Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort	31
Sugar‐sweetened beverages, artificially sweetened beverages and natural juices and risk of inflammatory bowel disease: a cohort study of 121,490 participants	31
Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver	30
Gut‐brain axis dysfunction underlies FODMAP‐induced symptom generation in irritable bowel syndrome	30
Comorbidity before and after a diagnosis of inflammatory bowel disease	30
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study	29
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohort	29
Clinical trial: seven‐day vonoprazan‐ versus 14‐day proton pump inhibitor‐based triple therapy for first‐line Helicobacter pylori eradication	29
Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study	29
Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis	28
Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis	28
Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease	28
Meta‐analysis: The efficacy of therapeutic drug monitoring of anti‐TNF‐therapy in inflammatory bowel disease	28
Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non‐alcoholic fatty liver disease	28
Vigorous physical activity provides protection against all‐cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)	28
Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease	28
Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease	28
One‐quarter of chronic hepatitis D patients reach HDV‐RNA decline or undetectability during the natural course of the disease	28
Nonselective beta‐blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States	27

Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease	27
Systematic review with meta‐analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases	27
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis	27
Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases	27
Systematic review with meta‐analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor	27
Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease	27
Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease	27
Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study	27
Factors associated with lower disease‐specific and generic health‐related quality of life in Rome IV irritable bowel syndrome	26
Carvedilol is associated with improved survival in patients with cirrhosis: a long‐term follow‐up study	26
Applying Lyon Consensus criteria in the work‐up of patients with proton pump inhibitory‐refractory heartburn	26
Review Article: vaccination for patients with inflammatory bowel disease during the COVID‐19 pandemic	26
Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn’s disease	26
The association between inflammatory bowel disease and mental ill health: a retrospective cohort study using data from UK primary care	26
Oesophageal hypervigilance and visceral anxiety relate to reflux symptom severity and psychological distress but not to acid reflux parameters	25
Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta‐analyses	25
Antibodies‐to‐infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease	25
Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis ‐ a unique therapeutic target in inflammatory bowel disease	25
Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease	25
One‐year outcomes with ustekinumab therapy in infliximab‐refractory paediatric ulcerative colitis: a multicentre prospective study	24
Applications of machine learning models in the prediction of gastric cancer risk in patients after Helicobacter pylori eradication	24
Stopping nucleot(s)ide analogues in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels	24
Higher mortality among lean patients with non‐alcoholic fatty liver disease despite fewer metabolic comorbidities	24
Toward transmural healing: Sonographic healing is associated with improved long‐term outcomes in patients with Crohn’s disease	24
Fatigue in inflammatory bowel disease and its impact on daily activities	24
Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID‐19: a self‐controlled case series study	23
Systematic review with meta‐analysis: the accuracy of serological tests to support the diagnosis of coeliac disease	23
Review article: Epidemiology of coeliac disease	23
Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population‐based cohort study	23
Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD	23
Systematic review with meta‐analysis: one‐year outcomes of gastric peroral endoscopic myotomy for refractory gastroparesis	23
Review article: current and emerging therapies for the management of cirrhosis and its complications	23
Role of smoking in functional dyspepsia and irritable bowel syndrome: three random population‐based studies	23
Colectomy rates for ulcerative colitis in England 2003‐2016	23
Systematic review: the role of psychological stress in inflammatory bowel disease	23
Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis	23
Progressive alcohol‐related liver fibrosis is characterised by imbalanced collagen formation and degradation	23
Anti‐glycoprotein 2 (anti‐GP2) IgA and anti‐neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3‐ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary s	23
Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management	23
A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II	22
Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis	22
Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know	22
Systematic review: development of a consensus code set to identify cirrhosis in electronic health records	22
MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective	22
Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis	22
Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti‐TNF: a French nationwide study 2010–2018	22
Systematic review—pancreatic involvement in inflammatory bowel disease	22
Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid	22
Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma	22
The disease severity index for inflammatory bowel disease is associated with psychological symptoms and quality of life, and predicts a more complicated disease course	22
Review article: The aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies	22
Longitudinal follow‐up study: effect of psychological co‐morbidity on the prognosis of inflammatory bowel disease	22
Dose–response relationships of accelerometer‐measured sedentary behaviour and physical activity with non‐alcoholic fatty liver disease	22
Prevalence, symptoms and risk factor profile of rumination syndrome and functional dyspepsia: a population‐based study	22
Systematic review and meta‐analysis: efficacy of peppermint oil in irritable bowel syndrome	21
Clinical classification and long‐term outcomes of seronegative coeliac disease: a 20‐year multicentre follow‐up study	21
Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct‐acting anti‐virals	21
The efficacy and safety of keverprazan, a novel potassium‐competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double‐blind multicentre study	21
Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates	21
Randomised clinical trial: a 12‐strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections	21
Systematic review with meta‐analysis: volatile organic compound analysis to improve faecal immunochemical testing in the detection of colorectal cancer	21
Risk of dementia in patients with inflammatory bowel disease: a Danish population‐based study	21
Longitudinal follow‐up of a novel classification system for irritable bowel syndrome: natural history and prognostic value	21
The impact of genetic risk on liver fibrosis in non‐alcoholic fatty liver disease as assessed by magnetic resonance elastography	21
Classic drugs in the time of new drugs: real‐world, long‐term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease	20
The impact of disease activity on psychological symptoms and quality of life in patients with inflammatory bowel disease—results from the Stress, Anxiety and Depression with Disease Activity (SADD) St	20
Effect of point‐of‐care gastrointestinal ultrasound on decision‐making and management in inflammatory bowel disease	20
An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials	20
Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero	20
Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study	20
Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis	20
PRO‐C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol‐related liver disease	20
Serum hepatitis B core‐related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load	20
A practical use of noninvasive tests in clinical practice to identify high‐risk patients with nonalcoholic steatohepatitis	20
Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)	20
Mild neoterminal ileal post‐operative recurrence of Crohn’s disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesions	20
Randomised clinical trial: high‐dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease	19
Autoimmune diseases in microscopic colitis: A Danish nationwide case–control study	19
Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis	19
Intestinal chemosensitivity in irritable bowel syndrome associates with small intestinal TRPV channel expression	19

Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study	19
A retrospective cohort study: pre‐operative oral enteral nutritional optimisation for Crohnʼs disease in a UK tertiary IBD centre	19
Increasing rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease: a nationwide analysis	19
Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue‐induced hepatitis B surface antigen loss	19
Incremental value of HBcrAg to classify 1582 HBeAg‐negative individuals in chronic infection without liver disease or hepatitis	19
Determinants of re‐compensation in patients with hepatitis B virus‐related decompensated cirrhosis starting antiviral therapy	19
Inflammatory bowel disease patient‐reported quality assessment should drive service improvement: a national survey of UK IBD units and patients	19
Review article: current and future treatment approaches for pain in IBS	19
NAFLD‐related gene polymorphisms and all‐cause and cause‐specific mortality in an Asian population: the Shanghai Changfeng Study	18
Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease	18
Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double‐blind, randomised, placebo‐controlled, phase 2 study	18
Comparison of gastrointestinal landmarks using the gas‐sensing capsule and wireless motility capsule	18
Clinical outcome after anti‐tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long‐term study	18
Review article: Physical and psychological comorbidities associated with irritable bowel syndrome	18
Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression	18
Strongly increased risk of gastric and duodenal ulcers among new users of low‐dose aspirin: results from two large cohorts with new‐user design	18
Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome	18
Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease	18
Outcomes after double switching from originator Infliximab to biosimilar CT‐P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12‐month prospective cohort study	18
Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma	17
Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers	17
Review article: Translating STRIDE‐II into clinical reality – Opportunities and challenges	17
Immune‐mediated diseases and risk of Crohn’s disease or ulcerative colitis: a prospective cohort study	17
Meta‐analysis: Real‐world effectiveness and safety of ustekinumab in patients with ulcerative colitis	17
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data	17
Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects	17
Review article: current gaps and opportunities in HBV prevention, testing and linkage to care in the United States—a call for action	17
Schizophrenia and risk of new‐onset inflammatory bowel disease: a nationwide longitudinal study	17
Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease	17
The diagnostic and prognostic significance of liver histology in alcoholic hepatitis	17
Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohnʼs disease	17
Root‐cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease	17
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study	17
Corticosteroid plus glycyrrhizin therapy for chronic drug‐ or herb‐induced liver injury achieves biochemical and histological improvements: a randomised open‐label trial	17
Trends in characteristics, management, and outcomes of patients presenting with gastrointestinal bleeding to emergency departments in the United States from 2006 to 2019	16
Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology	16
Review article: drug‐induced small bowel injury	16
Effects of social determinants of health on mortality and incident liver‐related events and cardiovascular disease in steatotic liver disease	16
Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus‐ and hepatitis C virus‐infected individuals	16
Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome	16
Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study	16
The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme	16
Review article: Putting some muscle into sarcopenia—the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease	16
Systematic review and network meta‐analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation	16
Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up	16
Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis	16
Non‐oesophageal eosinophilic gastrointestinal diseases are undersuspected clinically and underdiagnosed pathologically	16
Randomised clinical trial: the effects of pregabalin vs placebo on functional dyspepsia	16
Efficacy of ginger as antiemetic in children with acute gastroenteritis: a randomised controlled trial	16
Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance‐pH parameters implying anti‐reflux mechanism of action	16
Chicago classification v4.0 protocol improves specificity and accuracy of diagnosis of oesophagogastric junction outflow obstruction	16
Meta‐analysis: analysis of mechanistic pathways in the treatment of non‐alcoholic steatohepatitis. Evidence from a Bayesian network meta‐analysis	16
Epidemiology of Helicobacter pylori	16
Letter: budesonide for functional dyspepsia with duodenal eosinophilia—randomised, double‐blind, placebo‐controlled parallel‐group trial	15
The clinical course of Crohn’s disease in a Danish population‐based inception cohort with more than 50 years of follow‐up, 1962‐2017	15
Subcutaneous injection of infliximab CT‐P13 results in stable drug levels within 14‐day treatment cycle in Crohn’s disease	15
Review article: An analysis of the pharmacological rationale for selecting drugs to inhibit vomiting or increase gastric emptying during treatment of gastroparesis	15
Age determines the risk of familial inflammatory bowel disease—A nationwide study	15
An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials	15
Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome	15
TRIM26 inhibits hepatitis B virus replication by promoting HBx degradation and TRIM26 genetic polymorphism predicts PegIFNα treatment response of HBeAg‐pos	15
Durable virological response and functional cure of chronic hepatitis D after long‐term peginterferon therapy	15
Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population‐based cohort study	15
Use of statins after liver transplantation is associated with improved survival: results of a nationwide study	15
Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss	15
Review article: novel biomarkers in hepatitis B infection	15
Defining normal pouch function in patients with ileal pouch‐anal anastomosis: a pilot study	15
Predicting clinical decompensation in patients with cirrhosis using the Hepquant‐SHUNT test	15
Real‐world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel disease: ERELATE	15
Serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients	15
Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti‐TNF therapy in tuberculosis endemic region	15
Randomised controlled trial: effects of gluten‐free diet on symptoms and the gut microenvironment in irritable bowel syndrome	15
Review article: Elobixibat: a novel treatment for chronic constipation	15
Clinical utility of urinary gluten immunogenic peptides in the follow‐up of patients with coeliac disease	15
Clinical role of ambulatory reflux monitoring in PPI non‐responders: recommendation statements	15
Meta‐analysis: Use of proton pump inhibitors and risk of gastric cancer in patients requiring gastric acid suppression	15
Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS‐D) and IBS mixed pattern (IBS‐M)	15
Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome	15
Review article: hepatitis B—current and emerging therapies	15
Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy	15
Potential benefit and lack of serious risk from corticosteroids in drug‐induced liver injury: An international, multicentre, propensity score‐matched analysis	14
Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B	14
Medication use and microscopic colitis	14
Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension	14
Predictors of disease activity during pregnancy in women with inflammatory bowel disease—a Danish cohort study	14
Long‐term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication: a population‐based cohort study	14
Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer's global safety database	14
Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis	14
Meta‐analysis: The impact of light‐to‐moderate alcohol consumption on progressive non‐alcoholic fatty liver disease	14
Randomised study: effects of the 5‐HT₄ receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis	14
Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission	14
Non‐steroidal anti‐inflammatory drugs, polygenic risk score and colorectal cancer risk	14
Randomised, placebo‐controlled trial and meta‐analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial	14
Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK‐906), a dopamine D₂/D₃ receptor antagonist, in patients with gastroparesis	14
Systematic review with meta‐analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B	14